1 of 2
Global Microbiome Therapeutics Market to Reach $1.1 Billion by 2027
Amid the COVID-19 crisis, the global market for Microbiome Therapeutics estimated at US$46 Million in the year 2020, is projected to reach a revised size of US$1.1 Billion by 2027, growing at a CAGR of 58.1% over the analysis period 2020-2027. Type 2 Diabetes, one of the segments analyzed in the report, is projected to record a 66.4% CAGR and reach US$244.5 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Obesity segment is readjusted to a revised 59% CAGR for the next 7-year period.
The U.S. Market is Estimated at $14.1 Million, While China is Forecast to Grow at 54.6% CAGR
The Microbiome Therapeutics market in the U.S. is estimated at US$14.1 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$172.9 Million by the year 2027 trailing a CAGR of 54.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 53.1% and 48.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 37.8% CAGR.
C. Difficile Infection Segment to Record 49.1% CAGR
In the global C. Difficile Infection segment, USA, Canada, Japan, China and Europe will drive the 49.1% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$13.7 Million in the year 2020 will reach a projected size of US$224.1 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$135.8 Million by the year 2027.
Select Competitors (Total 46 Featured):
Amid the COVID-19 crisis, the global market for Microbiome Therapeutics estimated at US$46 Million in the year 2020, is projected to reach a revised size of US$1.1 Billion by 2027, growing at a CAGR of 58.1% over the analysis period 2020-2027. Type 2 Diabetes, one of the segments analyzed in the report, is projected to record a 66.4% CAGR and reach US$244.5 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Obesity segment is readjusted to a revised 59% CAGR for the next 7-year period.
The U.S. Market is Estimated at $14.1 Million, While China is Forecast to Grow at 54.6% CAGR
The Microbiome Therapeutics market in the U.S. is estimated at US$14.1 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$172.9 Million by the year 2027 trailing a CAGR of 54.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 53.1% and 48.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 37.8% CAGR.
C. Difficile Infection Segment to Record 49.1% CAGR
In the global C. Difficile Infection segment, USA, Canada, Japan, China and Europe will drive the 49.1% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$13.7 Million in the year 2020 will reach a projected size of US$224.1 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$135.8 Million by the year 2027.
Select Competitors (Total 46 Featured):
- 4D pharma plc
- AOBiome
- Enterome SA
- Evelo Biosciences, Inc.
- Ferring International
- Immuron Ltd.
- LNC Therapeutics
- Microbiome Therapeutics, LLC.
- Osel, Inc.
- OxThera AB
- Rebiotix, Inc.
- Ritter Pharmaceuticals, Inc.
- Second Genome
- Seres Therapeutics, Inc.
- Vedanta Biosciences, Inc.
- ViThera Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
2 of 2
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Impact of Covid-19 and a Looming Global Recession
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Current & Future Analysis for Microbiome Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
- Table 2: World 7-Year Perspective for Microbiome Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027
- Table 3: World Current & Future Analysis for Type 2 Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
- Table 4: World 7-Year Perspective for Type 2 Diabetes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
- Table 5: World Current & Future Analysis for Obesity by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
- Table 6: World 7-Year Perspective for Obesity by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
- Table 7: World Current & Future Analysis for C. Difficile Infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
- Table 8: World 7-Year Perspective for C. Difficile Infection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
- Table 9: World Current & Future Analysis for Primary Hyperoxyurea by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
- Table 10: World 7-Year Perspective for Primary Hyperoxyurea by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
- UNITED STATES
- Table 11: USA Current & Future Analysis for Microbiome Therapeutics by Segment - Type 2 Diabetes, Obesity, C. Difficile Infection and Primary Hyperoxyurea - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
- Table 12: USA 7-Year Perspective for Microbiome Therapeutics by Segment - Percentage Breakdown of Value Sales for Type 2 Diabetes, Obesity, C. Difficile Infection and Primary Hyperoxyurea for the Years 2020 & 2027
- CANADA
- Table 13: Canada Current & Future Analysis for Microbiome Therapeutics by Segment - Type 2 Diabetes, Obesity, C. Difficile Infection and Primary Hyperoxyurea - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
- Table 14: Canada 7-Year Perspective for Microbiome Therapeutics by Segment - Percentage Breakdown of Value Sales for Type 2 Diabetes, Obesity, C. Difficile Infection and Primary Hyperoxyurea for the Years 2020 & 2027
- JAPAN
- Table 15: Japan Current & Future Analysis for Microbiome Therapeutics by Segment - Type 2 Diabetes, Obesity, C. Difficile Infection and Primary Hyperoxyurea - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
- Table 16: Japan 7-Year Perspective for Microbiome Therapeutics by Segment - Percentage Breakdown of Value Sales for Type 2 Diabetes, Obesity, C. Difficile Infection and Primary Hyperoxyurea for the Years 2020 & 2027
- CHINA
- Table 17: China Current & Future Analysis for Microbiome Therapeutics by Segment - Type 2 Diabetes, Obesity, C. Difficile Infection and Primary Hyperoxyurea - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
- Table 18: China 7-Year Perspective for Microbiome Therapeutics by Segment - Percentage Breakdown of Value Sales for Type 2 Diabetes, Obesity, C. Difficile Infection and Primary Hyperoxyurea for the Years 2020 & 2027
- EUROPE
- Table 19: Europe Current & Future Analysis for Microbiome Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
- Table 20: Europe 7-Year Perspective for Microbiome Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027
- Table 21: Europe Current & Future Analysis for Microbiome Therapeutics by Segment - Type 2 Diabetes, Obesity, C. Difficile Infection and Primary Hyperoxyurea - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
- Table 22: Europe 7-Year Perspective for Microbiome Therapeutics by Segment - Percentage Breakdown of Value Sales for Type 2 Diabetes, Obesity, C. Difficile Infection and Primary Hyperoxyurea for the Years 2020 & 2027
- FRANCE
- Table 23: France Current & Future Analysis for Microbiome Therapeutics by Segment - Type 2 Diabetes, Obesity, C. Difficile Infection and Primary Hyperoxyurea - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
- Table 24: France 7-Year Perspective for Microbiome Therapeutics by Segment - Percentage Breakdown of Value Sales for Type 2 Diabetes, Obesity, C. Difficile Infection and Primary Hyperoxyurea for the Years 2020 & 2027
- GERMANY
- Table 25: Germany Current & Future Analysis for Microbiome Therapeutics by Segment - Type 2 Diabetes, Obesity, C. Difficile Infection and Primary Hyperoxyurea - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
- Table 26: Germany 7-Year Perspective for Microbiome Therapeutics by Segment - Percentage Breakdown of Value Sales for Type 2 Diabetes, Obesity, C. Difficile Infection and Primary Hyperoxyurea for the Years 2020 & 2027
- ITALY
- Table 27: Italy Current & Future Analysis for Microbiome Therapeutics by Segment - Type 2 Diabetes, Obesity, C. Difficile Infection and Primary Hyperoxyurea - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
- Table 28: Italy 7-Year Perspective for Microbiome Therapeutics by Segment - Percentage Breakdown of Value Sales for Type 2 Diabetes, Obesity, C. Difficile Infection and Primary Hyperoxyurea for the Years 2020 & 2027
- UNITED KINGDOM
- Table 29: UK Current & Future Analysis for Microbiome Therapeutics by Segment - Type 2 Diabetes, Obesity, C. Difficile Infection and Primary Hyperoxyurea - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
- Table 30: UK 7-Year Perspective for Microbiome Therapeutics by Segment - Percentage Breakdown of Value Sales for Type 2 Diabetes, Obesity, C. Difficile Infection and Primary Hyperoxyurea for the Years 2020 & 2027
- REST OF EUROPE
- Table 31: Rest of Europe Current & Future Analysis for Microbiome Therapeutics by Segment - Type 2 Diabetes, Obesity, C. Difficile Infection and Primary Hyperoxyurea - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
- Table 32: Rest of Europe 7-Year Perspective for Microbiome Therapeutics by Segment - Percentage Breakdown of Value Sales for Type 2 Diabetes, Obesity, C. Difficile Infection and Primary Hyperoxyurea for the Years 2020 & 2027
- ASIA-PACIFIC
- Table 33: Asia-Pacific Current & Future Analysis for Microbiome Therapeutics by Segment - Type 2 Diabetes, Obesity, C. Difficile Infection and Primary Hyperoxyurea - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
- Table 34: Asia-Pacific 7-Year Perspective for Microbiome Therapeutics by Segment - Percentage Breakdown of Value Sales for Type 2 Diabetes, Obesity, C. Difficile Infection and Primary Hyperoxyurea for the Years 2020 & 2027
- REST OF WORLD
- Table 35: Rest of World Current & Future Analysis for Microbiome Therapeutics by Segment - Type 2 Diabetes, Obesity, C. Difficile Infection and Primary Hyperoxyurea - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
- Table 36: Rest of World 7-Year Perspective for Microbiome Therapeutics by Segment - Percentage Breakdown of Value Sales for Type 2 Diabetes, Obesity, C. Difficile Infection and Primary Hyperoxyurea for the Years 2020 & 2027
- Total Companies Profiled: 46
Note: Product cover images may vary from those shown
